CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported routine equity compensation activity, including RSU vesting and a mandated tax-related sale. On March 14, 2026, 8,125 Restricted Stock Units converted into 8,125 Common Shares at $0.00 per share, representing the first quarter of a 32,500-share RSU grant awarded on March 14, 2025.

A separate footnote explains that 3,150 Common Shares were sold at $48.26 per share on March 16, 2026 solely to cover tax withholding obligations tied to this vesting, as required by the company’s RSU Settlement Policy, and that this did not represent a discretionary trade. Following these transactions, Patel directly owns 13,143 Common Shares, including 592 acquired under the 2016 Employee Stock Purchase Plan, and holds 24,375 unvested Restricted Stock Units that continue to vest annually through March 14, 2029.

Insider Trade Summary

Net Seller: 3,150 shares ($152,019)

Net Sell 3 txns

Insider Patel Naimish

Role Chief Medical Officer

Sold 3,150 shs ($152K)

Type	Security	Shares	Price	Value
Sale	Common Shares	3,150	$48.26	$152K
Exercise	Restricted Stock Units	8,125	$0.00	--
Exercise	Common Shares	8,125	$0.00	--

Holdings After Transaction: Common Shares — 13,143 shares (Direct); Restricted Stock Units — 24,375 shares (Direct)

Footnotes (1)

These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Includes 592 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

Form 4 Insider Transactions: What Each Field Means →

03/17/2026 - 05:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Naimish

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

02127

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	03/14/2026		M⁽¹⁾		8,125	A	⁽²⁾	16,293⁽³⁾	D
Common Shares	03/16/2026		S		3,150⁽⁴⁾	D	$48.26	13,143	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	03/14/2026		M⁽¹⁾			8,125	⁽⁵⁾	⁽⁵⁾	Common Shares	8,125	⁽²⁾	24,375	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Includes 592 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

4. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

5. This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CRISPR Therapeutics (CRSP) CMO Naimish Patel report?

Naimish Patel reported RSU vesting and a related tax sale. 8,125 Restricted Stock Units converted into Common Shares, and 3,150 Common Shares were sold at $48.26 per share to satisfy tax withholding obligations under the company’s RSU Settlement Policy.

Was the CRISPR Therapeutics (CRSP) insider stock sale by the CMO discretionary?

The 3,150-share sale was not discretionary. A footnote states the sale was mandated by CRISPR Therapeutics’ RSU Settlement Policy solely to cover tax withholding from RSU vesting, and explicitly notes it does not represent a discretionary trade by Naimish Patel.

How many CRISPR Therapeutics (CRSP) shares does the CMO hold after these transactions?

After the reported transactions, Naimish Patel directly owns 13,143 Common Shares. This figure includes 592 shares acquired through the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan, according to the holding information provided in the filing data.

What Restricted Stock Unit grant is vesting for CRISPR Therapeutics (CRSP) CMO Naimish Patel?

Patel holds an RSU award granted on March 14, 2025 covering 32,500 Common Shares. One quarter, or 8,125 shares, vested on March 14, 2026, with additional 8,125-share tranches scheduled to vest annually through March 14, 2029, subject to continued service.

How many unvested RSUs does the CRISPR Therapeutics (CRSP) CMO still have outstanding?

Following the initial vesting, Naimish Patel has 24,375 Restricted Stock Units outstanding. Each RSU represents a contingent right to receive one CRISPR Therapeutics Common Share, with remaining tranches vesting in equal annual installments from 2027 through 2029.